ADC Therapeutics SA Adjustments For Finance Income
ADC Therapeutics SA (ADCT) reported Adjustments For Finance Income of $2.30 million for the 3-month period ending 2023-03-31, per its 6-K filed 2023-05-09.
Discontinued › Income Statement › Other Income
ifrs-full:AdjustmentsForFinanceIncome · last filed 2023-05-09
- ADC Therapeutics SA adjustments for finance income for the quarter ending 2023-03-31 was $2.30M, a 87.41% decline year-over-year.
- ADC Therapeutics SA adjustments for finance income for the quarter ending 2022-12-31 was -$627.00K, a 3235.00% decline year-over-year.
- ADC Therapeutics SA adjustments for finance income for the quarter ending 2022-09-30 was $273.00K, a 1606.25% increase year-over-year.
- ADC Therapeutics SA adjustments for finance income for the quarter ending 2022-06-30 was $17.00K, a 13.33% increase year-over-year.
| Period end | Adjustments For Finance Income 3 month | Adjustments For Finance Income 6 month | Adjustments For Finance Income 9 month | Adjustments For Finance Income 12 month |
|---|---|---|---|---|
| 2023-03-31 | $2.30M 6-K · filed 2023-05-09 | $1.68M derived: sum of 2 quarters · filed 2023-05-09 | $1.95M derived: sum of 3 quarters · filed 2023-05-09 | $1.97M derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | -$627.00K derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | -$354.00K derived: sum of 2 quarters · filed 2023-03-15 | -$337.00K derived: sum of 3 quarters · filed 2023-03-15 | $17.97M 20-F · filed 2023-03-15 |
| 2022-09-30 | $273.00K derived: 6-K 9 month − 6-K 6 month · filed 2022-11-08 | $290.00K derived: sum of 2 quarters · filed 2022-11-08 | $18.60M 6-K · filed 2022-11-08 | $18.62M derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-06-30 | $17.00K derived: 6-K 6 month − 6-K 3 month · filed 2022-08-09 | $18.32M 6-K · filed 2022-08-09 | $18.34M derived: sum of 3 quarters · filed 2023-05-09 | $18.36M derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-03-31 | $18.31M 6-K · filed 2023-05-09 | $18.33M derived: sum of 2 quarters · filed 2023-05-09 | $18.34M derived: sum of 3 quarters · filed 2023-05-09 | $18.36M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $20.00K derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $36.00K derived: sum of 2 quarters · filed 2023-03-15 | $51.00K derived: sum of 3 quarters · filed 2023-03-15 | $66.00K 20-F · filed 2023-03-15 |
| 2021-09-30 | $16.00K derived: 6-K 9 month − 6-K 6 month · filed 2022-11-08 | $31.00K derived: sum of 2 quarters · filed 2022-11-08 | $46.00K 6-K · filed 2022-11-08 | $146.00K derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-06-30 | $15.00K derived: 6-K 6 month − 6-K 3 month · filed 2022-08-09 | $30.00K 6-K · filed 2022-08-09 | $130.00K derived: sum of 3 quarters · filed 2023-03-15 | $293.00K derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-03-31 | $15.00K 6-K · filed 2022-05-09 | $115.00K derived: sum of 2 quarters · filed 2023-03-15 | $278.00K derived: sum of 3 quarters · filed 2023-03-15 | $473.00K derived: sum of 4 quarters · filed 2023-03-15 |
| 2020-12-31 | $100.00K derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $263.00K derived: sum of 2 quarters · filed 2023-03-15 | $458.00K derived: sum of 3 quarters · filed 2023-03-15 | $832.00K 20-F · filed 2023-03-15 |
| 2020-09-30 | $163.00K derived: 6-K 9 month − 6-K 6 month · filed 2021-11-02 | $358.00K derived: sum of 2 quarters · filed 2021-11-02 | $732.00K 6-K · filed 2021-11-02 | |
| 2020-06-30 | $195.00K derived: 6-K 6 month − 6-K 3 month · filed 2021-08-03 | $569.00K 6-K · filed 2021-08-03 | ||
| 2020-03-31 | $374.00K 6-K · filed 2021-05-06 | |||
| 2019-12-31 | $1.70M 20-F · filed 2022-03-17 | |||
| 2018-12-31 | $1.85M 20-F · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |